# EDGAR Filing Document

**Accession Number:** 0001352546
**File Stem:** 0001193805-25-000929
**Filing Date:** 2025-6
**Character Count:** 13209
**Document Hash:** e6e64115bd8d936a62d7b0a84ef959a4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193805-25-000929.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001193805-25-000929

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250618

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
- **CENTRAL INDEX KEY:** 0001009258

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40671
- **FILM NUMBER:** 251062785

**BUSINESS ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH, 12TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 2125511600

**MAIL ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH, 12TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER NAME:**
- **FORMER CONFORMED NAME:** DEERFIELD MANAGEMENT CO
- **DATE OF NAME CHANGE:** 20131114

**FORMER NAME:**
- **FORMER CONFORMED NAME:** DEERFIELD MANAGEMENT CO /NY
- **DATE OF NAME CHANGE:** 19981022
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Flynn James E
- **CENTRAL INDEX KEY:** 0001352546

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40671
- **FILM NUMBER:** 251062786

**MAIL ADDRESS:**
- **STREET 1:** 780 THIRD AVENUE
- **STREET 2:** 37TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nuvalent, Inc.
- **CENTRAL INDEX KEY:** 0001861560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BROADWAY, 14TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 508-446-2272

**MAIL ADDRESS:**
- **STREET 1:** ONE BROADWAY, 14TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

## Ex-99

Joint Filer Information

---

| | |
|:---|:---|
| Names: | Deerfield Management Company, L.P. |
| Address: | 345 Park Avenue South, 12<sup>th</sup> Floor<br> New York, NY 10010 |
| Designated Filer: | James E. Flynn |
| Issuer and Ticker Symbol: | Nuvalent, Inc. [NUVL] |
| Date of Event Requiring Statement: | June 18, 2025 |

---

The undersigned, Deerfield Management Company, L.P., is jointly filing the attached Statement of Changes in Beneficial Ownership on Form 4 with James E. Flynn with respect to the beneficial ownership of securities of Nuvalent, Inc.

Signatures:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DEERFIELD MANAGEMENT COMPANY, L.P.<br> By: Flynn Management LLC, General Partner<br>By: <u>/s/ Jonathan Isler</u><br> Jonathan Isler, Attorney-In-Fact<br>

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Flynn James E<br><sub>(Last) (First) (Middle)</sub><br>345 PARK AVENUE SOUTH, 12TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Director by Deputization_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Nuvalent, Inc. [ NUVL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)<br><sub>(Last) (First) (Middle)</sub><br>345 PARK AVENUE SOUTH, 12TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Director by Deputization_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Nuvalent, Inc. [ NUVL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2025-06-18 |  | A |  | 2647<sup>(1)</sup> | A | $0 | 2647<sup>(1)</sup> | I | Through Deerfield Management Company, L.P.<sup>(1)(3)(7)</sup> |
| Class A Common Stock | 2025-06-18 |  | A |  | 2647<sup>(2)</sup> | A | $0 | 2647<sup>(2)</sup> | I | Through Deerfield Management Company, L.P.<sup>(2)(3)(7)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 4998 | I | Through Deerfield Management Company, L.P.<sup>(3)(6)(7)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 650000 | I | Deerfield Partners, L.P.<sup>(3)(7)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 8670512 | I | Through Deerfield Private Design Fund IV, L.P.<sup>(3)(7)</sup> |
| Class A Common Stock |  |  |  |  |  |  |  | 8670512 | I | Through Deerfield Healthcare Innovations Fund, L.P.<sup>(3)(7)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $75.53 | 2025-06-18 |  | A |  | 4147<sup>(4)</sup> |  | <sup>(4)</sup> | 2035-06-18 | Class A Common Stock | 4147<sup>(4)</sup> | $0 | 4147<sup>(4)</sup> | I | Through Deerfield Management Company, L.P.<sup>(3)(4)(7)</sup> |
| Stock Option (Right to Buy) | $75.53 | 2025-06-18 |  | A |  | 4147<sup>(5)</sup> |  | <sup>(5)</sup> | 2035-06-18 | Class A Common Stock | 4147<sup>(5)</sup> | $0 | 4147<sup>(5)</sup> | I | Through Deerfield Management Company, L.P.<sup>(3)(5)(7)</sup> |

---

### Footnotes:

(1) Cameron Wheeler, a partner in Deerfield Management Company, L.P. ("Deerfield Management"), serves as a director of the Issuer. The reported shares of Class A Common Stock are issuable under restricted stock units ("RSUs") granted to Mr. Wheeler, which are held for the benefit, and at the direction, of Deerfield Management. Each RSU represents the right to receive one share of the Issuer's Class A Common Stock. The RSUs vest in full on the earlier of June 18, 2026 or the date of the Issuer's next annual meeting of stockholders, subject to Mr. Wheeler's continued service to the Issuer through the applicable vesting date.

(2) Joseph Pearlberg, an employee of Deerfield Management, serves as a director of the Issuer. The reported shares of Class A Common Stock are issuable under restricted stock units ("RSUs") granted to Mr. Pearlberg, which are held for the benefit, and at the direction, of Deerfield Management. Each RSU represents the right to receive one share of the Issuer's Class A Common Stock. The RSUs vest in full on the earlier of June 18, 2026 or the date of the Issuer's next annual meeting of stockholders, subject to Mr. Pearlberg's continued service to the Issuer through the applicable vesting date.

(3) This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Deerfield Partners and Fund IV, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.

(4) The option was granted to Mr. Wheeler on June 18, 2025 and is scheduled to vest and become exercisable on the earlier of June 18, 2026 and the date of the Issuer's next annual meeting of stockholders, subject to Mr. Wheeler's continued service to the Issuer through the applicable vesting date. Such Option is held for the benefit, and at the direction, or Deerfield Management.

(5) The option was granted to Mr. Pearlberg on June 18, 2025 and is scheduled to vest and become exercisable on the earlier of June 18, 2026 and the date of the Issuer's next annual meeting of stockholders, subject to Mr. Pearlberg's continued service to the Issuer through the applicable vesting date. Such Option is held for the benefit, and at the direction, or Deerfield Management.

(6) Represents shares underlying fully vested restricted stock units originally issued to Messrs. Wheeler and Pearlberg, which shares are held for the benefit, and at the direction, of Deerfield Management.

(7) For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

**Remarks:**
Each of Cameron Wheeler, who is a partner in Deerfield Management, and Joseph Pearlberg, who is an employee of Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

**Signature:** /s/ Jonathan Isler, Attorney-in-Fact  
**Date:** 2025-06-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**